MARKET

NVO

NVO

Novo Nordisk
NYSE

Real-time Quotes | Nasdaq Last Sale

100.70
-1.40
-1.37%
Pre Market: 100.30 -0.4 -0.40% 06:11 09/27 EDT
OPEN
100.65
PREV CLOSE
102.10
HIGH
101.59
LOW
100.39
VOLUME
16
TURNOVER
--
52 WEEK HIGH
107.24
52 WEEK LOW
63.22
MARKET CAP
174.72B
P/E (TTM)
33.03
1D
5D
1M
3M
1Y
5Y
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
Zacks.com · 2d ago
Sector Update: Health Care
MT Newswires · 2d ago
BRIEF-Novo Nordisk To Pay $100 Mln In Settlement Agreement
reuters.com · 2d ago
HHS threatens six pharmas with fines over 340B drug discount program
HHS has sent letters to six pharmaceutical companies saying they may now face fines for refusing to appropriately comply with the federal government's 340B drug discount program. The companies are: AstraZeneca
Seekingalpha · 3d ago
‘High growth, low risk, high quality’: Bank of America backs these global stocks
BofA likes these large cap stocks it says will do well despite a slowdown in economic growth.
CNBC.com · 4d ago
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 20 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 A...
GlobeNewswire · 09/20 10:19
Novo Is Said to Explore Sale of Specialty Drugmaker Xellia
Bloomberg · 09/17 21:33
BRIEF-Exscientia Files For U.S. IPO
reuters.com · 09/10 15:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVO. Analyze the recent business situations of Novo Nordisk through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVO stock price target is 116.53 with a high estimate of 118.08 and a low estimate of 114.98.
EPS
Institutional Holdings
Institutions: 941
Institutional Holdings: 147.79M
% Owned: 8.52%
Shares Outstanding: 1.74B
TypeInstitutionsShares
Increased
248
3.39M
New
81
1.36M
Decreased
227
3.67M
Sold Out
46
363.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Independent Director
Helge Lund
President/Chief Executive Officer
Lars Fruergaard Joergensen
Vice Chairman/Director
Jeppe Christiansen
Chief Financial Officer/Executive Vice President/Primary Contact
Karsten Munk Knudsen
Chief Operating Officer/Executive Vice President
Maziar Doustdar
Executive Vice President/Chief Scientific Officer
Mads Krogsgaard Thomsen
Executive Vice President/Director of Human Resources
Monique Carter
Executive Vice President
Ludovic Helfgott
Executive Vice President
Douglas Langa
Executive Vice President
Camilla Sylvest
Executive Vice President
Henrik Wulff
Director
Mette Boejer Jensen
Director
Kasim Kutay
Director
Anne Kverneland
Director
Thomas Rantzau
Director
Stig Stroebaek
Independent Director
Brian Daniels
Independent Director
Laurence Debroux
Independent Director
Andreas Fibig
Independent Director
Sylvie Gregoire
Independent Director
Liz Hewitt
Independent Director
Martin Mackay
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.3867
08/16/2021
--
Dividend USD 0.6631491
03/26/2021
08/06/2020
Dividend USD 0.3679776
08/14/2020
02/06/2020
Dividend USD 0.5613016
03/27/2020
08/09/2019
Dividend USD 0.31809
08/16/2019
03/26/2019
Dividend USD 0.557215
03/22/2019
08/21/2018
Dividend USD 0.327
08/17/2018
--
Dividend USD 0.578
03/23/2018
08/10/2017
Dividend USD 0.336
08/17/2017
03/28/2017
Dividend USD 0.479
03/23/2017
08/16/2016
Dividend USD 0.331
08/11/2016
03/24/2016
Dividend USD 0.699
03/18/2016
03/25/2015
Dividend USD 0.533
03/19/2015
03/27/2014
Dividend USD 0.606
03/21/2014
03/26/2013
Dividend USD 0.453
03/21/2013
  • All
  • Financials
  • Insiders
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers kinds of Novo Nordisk A/S (ADR) stock information, including NYSE:NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.